Expanded Access RBS2418 Treatment

NCT05683470 | Unknown

• 1 other identifier: RBS2418-EA-002
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is an expanded access treatment protocol designed to provide access of RBS2418 to a single patient with pancreatic cancer.

Conditions

Expanded Access in Pancreatic Cancer

Interventions

RBS2418 DRUG

RBS2418 will be administered orally at 200 mg two times per day (BID).

Eligibility Criteria

• Sex: female
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• The patient is willing and able to provide informed consent. Only the patient for whom this clinical study/experimental treatment was designed will be given the investigational drug under the treatment of the PI. No other patient is authorized to participate in or to receive treatment under this treatment protocol.

You may not qualify if:

• Not applicable

Sponsors & Collaborators

• Riboscience, LLC.: lead
• Dr. Bertrand Tuan: collaborator

Study Officials

• Bertrand Tuan, MD

  Pacific Hematology and Oncology Associates

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 26, 2022
• First Posted: January 13, 2023
• Last Updated: February 21, 2024

Record last verified: 2024-02